Orforglipron
About
About Orforglipron
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken as a once-daily oral pill, representing the first oral GLP-1 agent that does not require food-timing restrictions unlike semaglutide tablets. Phase III trials show approximately 9% weight loss at 36 weeks with a favorable tolerability profile. Developed by Eli Lilly, it may offer broader accessibility due to its oral bioavailability and lack of cold-chain requirements.
Science
Mechanism of Action
Binds the GLP-1 receptor as a small-molecule allosteric agonist, producing appetite suppression, delayed gastric emptying, and enhanced glucose-dependent insulin secretion through the same receptor pathway as peptide GLP-1 analogs but via oral bioavailable formulation.
Dosing
Typical Protocol
3–36 mg oral tablet once daily regardless of food; Phase III dosing titration over 16 weeks.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Orforglipron — with trust scores, legal credentials, and pricing transparency.